Stock Financial Ratios


RARX / Ra Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price8.11
Volume110,000.00
Market Cap ($M)60.38
Enterprise Value ($M)-36.23
Book Value ($M)117.22
Book Value / Share28.35
Price / Book0.52
NCAV ($M)120.08
NCAV / Share29.04
Price / NCAV2.45
Income Statement (mra) ($M)
Revenue4.93
EBITDA-28.02
Net Income-28.86
Balance Sheet (mrq) ($M)
Cash & Equivalents84.09
Cash / Share20.33
Assets92.91
Liabilities10.33
Quick Ratio17.74
Current Ratio17.74
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.25
Return on Assets (ROA)-0.23
Return on Equity (ROE)-0.25
Identifiers and Descriptors
CUSIP74933V108
Central Index Key (CIK)1481512
Industry Groups
Share Statistics
Common Shares Outstanding (M)22.63
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Per Share22.47
Liabilities Per Share2.50
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Assets Current Per Share20.61
Retained Earnings Per Share-26.13
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Goodwill Per Share0.04
Accounts Receivable Per Share0.00
Intangibles Per Share0.05
Inventory Raw Materials Per Share0.00
Cash And Equivalents Per Share20.33
Long Term Debt Per Share0.00
Liabilities And Stock Equity Per Share22.47
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Property Plant And Equipment Gross Per Share2.23
Property Plant And Equipment Net Per Share1.44
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Equity Per Share19.97
Property Plant And Equipment Per Share1.44
Accumulated Depreciation And Depletion Per Share0.79
Treasury Stock Per Share0.00
Cash Per Share20.33
Liabilities Current Per Share1.89
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Additional Paid In Capital Per Share46.10

Related News Stories

Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value

2018-01-09 seekingalpha
Achillion (ACHN) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. (303-2)

Alexion Pharmaceuticals: A High Conviction, Large Cap Orphan Disease Pick For 2018

2018-01-08 seekingalpha
We are initiating coverage on Alexion Pharmaceuticals stock with a Buy rating and first price target of $170, 1-2 year time frame. (77-0)

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC

2017-12-21 reuters
* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS (18-0)

Waiting For A Pullback In Alexion Pharmaceuticals

2017-08-15 seekingalpha
Today we look at mid-cap biotech concern Alexion Pharmaceuticals which recently delivered better than expected quarterly results.

CUSIP: 74933V108